ATRC vs MESO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ATRC has a Piotroski F-Score of 5/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong revenue growth (15.8% YoY) and impressive earnings surprise trends, yet remains unprofitable with negative margins and ROE. High valuation multiples and insider selling offset bullish analyst sentiment and improving operational trends. The stock trades at a premium to the target, suggesting limited near-term upside despite growth potential.
MESO presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete absence of deterministic value markers like the Graham Number. While revenue growth is explosive (1526.8%), the company suffers from a catastrophic negative gross margin of -35.53%, meaning it loses money on its core product delivery. The valuation is extreme, with a Price-to-Book ratio of 32.96 and a Price-to-Sales ratio of 29.42, indicating the stock is priced for perfection despite consistent quarterly losses over several years.
Compare Another Pair
Related Comparisons
ATRC vs MESO: Head-to-Head Comparison
This page compares AtriCure, Inc. (ATRC) and Mesoblast Limited (MESO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.